Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tušek, Srećko"'
Autor:
Zinman, Bernard, Tušek, Srećko, Mirošević, Gorana, Goldoni, Vesna, Jurišić- Eržen, Dubravka, Balaško, Annemarie, Balić, Stjepan, Drvodelić- Šunić, Ema, Canecki Varžić, Silvija, Fitchett, David
Publikováno v:
Diabetologia (Berlin)
Volume 61
Issue 7
Volume 61
Issue 7
Aims/hypothesis The global epidemic of type 2 diabetes affects women and men equally ; however, the relative impact on the cardiovascular (CV) system appears greater for women than men when compared with peers without diabetes. Furthermore, women are
Autor:
Rodbard, HW, Rosenstock, J, Canani, LH, Deerochanawong, C, Gumprecht, J5, Lindberg, SØ, Lingvay, I, Søndergaard, AL, Treppendahl, MB, Montanya, E, Cruz, P, Loredo, L, Luquez, C, Moisello, M, Augusto, GA, Castro, M, Canani, L, Akrap, Branko, Bulum, Tomislav, Rahelić, Dario, Šunić-Grčić, Ivana, Tušek, Srećko, Avramidis, I, Benroubi, M, Didangelos, T, Karousos, G, Pagkalos, E, Sampanis, C, Somali, M, Domboróczki, Z, Faludi, P, Gaál, Z, Kis- Gombos, P, Kocsis, G, Marton, Z, Sudár, Z, Buscemi, S, Di Carlo, A, Dotta, F, Gambineri, A, Lauro, D, Maranghi, M, Arciszewska, M, Gumprecht, J, Matuszewska, K, Skokowska, E, Stasinska, T, Feofanova, S, Filippova, E, Galstyan, G, Gaysina, L, Kunitsyna, M, Suplotova, L, Antic, S, Djukic, A, Mitrovic, M, Pesic, M, Stokic, E, Jodar, E, Martínez, E, Raya, PM, Portillo, CM, Vera, MP, Fernández, MR, San Jose, P, Riera, MT, Boonyavarakul, A, Sriwijitkamol, A, Ajani, D, Armas, E, Barbel- Johnson, K, Bartilucci, D, Bonabi, G, Busch, R, Butuk, D, Cannon, K, Chase, C, Chaykin, L, Cheekati, V, Davis, T, Delgado, B, Farris, N, Graves, M, Ha, C, Harper, L, Herring, S, Hewitt, M, Hsia, D, Jackson, R, Jardula, M, Joyce, M, Juarez, M, Kapoor, A, Karounos, D, Kayne, D, Lacour, A, Ledesma, G, Lipetz, R, Lomboy, J, Lynd, S, Morawski, E, Morin, R, Murphy, R, Overcash, JS, Pullman, J, Ruoff, G, Steenkamp, D, Toro, H, Trachtenbarg, D, Tulloch, B, Weisbrot, A, Wright, A.
OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11d426d2138bca66de639b58bfb9884d
https://doi.org/10.2337/dc19-0883
https://doi.org/10.2337/dc19-0883
Autor:
Kaku, Kohei, Tušek, Srećko, Mirošević, Gorana, Goldoni, Vesna, Jurišić-Eržen, Dubravka, Balaško, Annemarie, Balić, Stjepan, Drvodelić- Šunić, Ema, Canecki Varžić, Silvija, Woerle, Hans-Juergen
Background: In the EMPA-REG OUTCOME (R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::bb3e5470e45fce22b60b8c0de5134931
https://www.bib.irb.hr/1121066
https://www.bib.irb.hr/1121066
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.